(Q34181862)

English

Nelfinavir mesylate

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

Nelfinavir mesylate (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

author name string

Tebas P

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Powderly WG

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1429-1440

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Response to ‘Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy’ by Drs Weil and Lenhard

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Rational design of peptide-based HIV proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.1.7.1429

21 January 2018

Identifiers

10.1517/14656566.1.7.1429

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34181862&oldid=1982110476"